UNIVERSITY^{OF} BIRMINGHAM

University of Birmingham Research at Birmingham

Complementary and alternative medicines use in COVID-19

Paudyal, Vibhu; Sun, Shusen; Hussain, Rabia; Abutaleb, Mohammed H.; Hedima, Erick Wesley

DOI:

10.1016/j.sapharm.2021.05.004

License

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version
Peer reviewed version

Citation for published version (Harvard):

Paudyal, V, Sun, S, Hussain, R, Abutaleb, MH & Hedima, EW 2021, 'Complementary and alternative medicines use in COVID-19: a global perspective on practice, policy and research', *Research in Social and Administrative Pharmacy*. https://doi.org/10.1016/j.sapharm.2021.05.004

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)

•Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 08. May. 2024

[Commentary]

Complementary and alternative medicines use in COVID-19: a global perspective on practice, policy and research

Introduction

Since the first cluster of cases identified in December 2020 in Wuhan China, COVID-19 was declared a global pandemic in March 2020. As of April 2021, the pandemic has caused over 3 million deaths globally. Currently, the approved vaccines and public health prevention measures such as social distancing, hand hygiene, contact tracing, and lockdown policies remain the mainstay of COVID-19 mitigation measures.

While the emergence of effective vaccines has offered the Governments, scientific communities, and members of the public a hope out of the pandemic, effective pharmacotherapy, including immunotherapy for COVID-19 prevention and treatment, is yet to be established. Some of the early treatments recommended for COVID-19 treatments, including hydroxychloroquine, and remdesivir have demonstrated limited effectiveness in early clinical trials.^{2,3} Currently, steroids, including dexamethasone, remain the only treatment proven to be effective in clinical trials in terms of mortality and hospitalization outcomes.⁴ Patients and members of public across the world are known to be relying on self-care practices including the use of Complementary and Alternative Medicines (CAM) for COVID-19 prevention and symptoms relief.

CAM refers to broad sets of practices, which are not fully integrated into the dominant healthcare system and can include herbal treatments, yoga, and relaxation techniques.⁵ These have been used by diverse communities across the world for thousands of years for the prevention and treatment of long-term health conditions and acute illnesses such as the treatment of respiratory infections. A recent systematic review of CAM use in diabetes listed over 37 different CAM types and 223 herbs used by patients.⁶ It is estimated that up to 70% of the low and middle-income countries (LMICs) are known to rely partly or entirely on the use of CAM to treat their health problems.⁷ Over 50% of the 194 WHO member states are currently known to have a national policy on CAM use (WHO).⁸

Given the lack of adequate pharmacotherapeutic approaches to COVID-19, a surge in demand for the information and CAM products has been noted in the popular media. A recent study on the impact of the COVID-19 pandemic on clinical pharmacy practice suggested pharmacists being increasingly requested information about dietary supplementation, vitamins, and any options on the shelves that could offer symptom relief and boost immune system.⁹ This narrative will aim to discuss global practices and policies in regards to CAM use in COVID-19. A global

39 update will enable understanding of international practices and policies, patient and consumer behaviors, identification of popular CAMs and those tipped for potential benefits, including 40 evidence base, and thereby support counselling and communications by healthcare 41 professionals when patients present for advice. The following section will summarize information 42 43 relevant to different geographical regions with a historical, religious, and cultural association with 44 CAM use. 45 46 China 47 Traditional Chinese Medicines (TCM) have been utilized extensively in treating COVID-19 patients in China during the outbreak. Personalized treatment through syndrome differentiation, 48 49 unique characteristics of TCM, is appealing to clinicians. Syndrome differentiation is a summary 50 of the pathological signs of the body at a specific stage during disease development, based on the synthesized data collected with the four diagnostic methods: observation, listening and 51 smelling, asking, and palpation and pulse-taking. 10 Thus, TCM is recommended as a COVID-19 52 treatment option in the China National Health Commission (NHC) guidelines. 11 53 54 55 Currently, 15 TCMs are recommended with seven oral formulations (Angong Niuhuang, Zixue, Huoxiang Zhengqi, Jinhua Qinggan, Lianhua Qingwen, Shufeng Jiedu, and Fangfeng 56 57 Tongsheng), and eight injectable formulations (Xiyanping, Xuebijing, Reduning, Tanreging, Xingnaojing, Shenfu, Shengmai, and Shenmai). The China Food and Drug Administration 58 59 (CFDA) has approved Xuebijing with a treatment indication of 'new coronavirus pneumonia with severe and critical systemic inflammatory response syndrome or/and multiple organ failure', and 60 Lianhua Qingwen with a new indication of 'treating for fever, cough, and fatigue caused by the 61 62 light and ordinary types of the new coronavirus pneumonia. 12 Each TCM formulation contains 63 several active ingredients with proven multi-target effects, making it challenging to develop drug resistance. Many TCM formulations also possess potent anti-inflammatory and 64 65 immunomodulatory effects. TCM clinical pharmacists play an active role in reviewing TCM prescriptions, preparing TCM decoctions, therapeutic monitoring, patient education, science 66 67 popularization, and clinical research. 13 Numerous trials are currently taking place in China 68 assessing the effectiveness of the products in COVID-19 treatment.¹⁴ 69 70 **South Asia** 71 The use of CAM is widespread and is culturally embedded in the countries belonging to the 72 South Asian region, including Pakistan, India, Bangladesh, Nepal, Sri Lanka, Afghanistan, 73 Bhutan, and Maldives. 15-17 A study from the COVID-19 isolation center in India suggested that 74 over a quarter (25.8%) of patients used CAM during their treatment and afterwards. 18 CAM practices prevalent in the area include Ayurveda, Unani, Reiki, Homeopathy, Biochemy, 75

and Aromatherapy. For example, since the beginning of the Indus civilization, Pakistan has a

long history of using herbal medicines. Up to 80% of the population use CAM, including herbal products, in their daily practice. Traditional medicine-based therapy, including Unani and homeopathic systems, is considered a vital source of healthcare in the region, especially in rural areas, where CAM serves as the first line of therapy. 15, 16

Culture, lack of access to modern medicines, and cost considerations are essential factors of CAM use in South Asia. CAM is embedded in the policy and healthcare practices in the region. For example, in 2001, "Traditional and Complementary Medicines" was included and adopted in Pakistan's National Health Policy. 8 The Indian Ministry of Health has established the Ayurveda, Yoga, Unani, Siddha, and Homeopathy, namely AYUSH (Ayurvedic, Yoga, and Naturopathy, Unani, Siddha, and Homeopathy) department that was later formed as Ministry of AYUSH in 2014 which has produced specific COVID-19 prevention and treatment guidelines for CAM practitioners.¹⁹ The guidelines advocate the use of yoga and herbal products such as Embilica officinalis (Indian gooseberry), Ocimum tenuiflorum (basil) and some branded herbal formulations as immune boosters. Other herbs of relevance in South Asia include curcumin, quinine, and echinacea for their respective antimicrobial, antiviral, anti-inflammatory, and immuno-booster activities.²⁰ Limited evidence, however, has been published in relation to effectiveness of such herbal remedies. In vitro studies in India demonstrated Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy), and Ocimum sanctum (Tulsi) linked to protease inhibition activities of SARS-CoV-2 virus.²¹ In addition, the World Health Organization (WHO) has acknowledged the effectiveness of Artemisia annua (a medicinal plant- abundantly available in both India and Pakistan) as a potential pharmacotherapy research candidate against COVID-19.^{22, 23}

Middle East

CAM is commonly used in the Middle East because it is linked to Islamic history with herbal treatments mentioned in Quran and is often known in the region as 'Arabic' or 'Islamic' medicine. CAM use is expected to grow at a compound annual growth rate of 22.8% from 2020 to 2027.²⁴ Since the pandemic reached the area CAM use is known to be common in the region.

In a recent study conducted in Saudi Arabia, over 1 in 5 (22.1%) of the 5258 survey respondents acknowledged their use of herbal products during the pandemic period because they believed that they are effective for the prevention of COVID-19.²⁵ Meditation or holy Quran recitation, cupping therapy (Hijama), acupuncture, massage, specific nutritional tonics, and herbs such as honey, dates, figs, peaches, garlic, olives, Anthemis hyalina (chamomile) and black cumin seeds are amongst the CAMs used for prevention and relief of symptoms include fatigue, loss of smell and breathing difficulties linked to COVID-19.²⁶ Nigella sativa when combined with grinded Anthemis hyaline and honey (TaibUVID was referred to prevention and treatment potential.^{27, 28} Other herbal products described in the literature include garlic, onions, and ginger preparations.²⁹

Several clinical trials on CAM have been registered in the Middle-east, notably, the phase II trial in Israel on the phytocannabinoid cannabidiol.³⁰ It is a non-psychotropic constituent of Cannabis sativa and possesses potent anti-inflammatory and immunosuppressive effects. These effects are mediated through the inhibition of proinflammatory cytokine release and stimulation of anti-inflammatory cytokine production.³⁰ A clinical trial in Egypt aims to evaluate the therapeutic potential of liquorice extract and Boswellia serrata gum.³¹ These plants are reported to have anti-inflammatory, antiviral, antithrombotic, and immunomodulatory properties.^{32, 33} A clinical trial in Iran aims to assess the effectiveness of colchicine combined with, herbal phenolic monoterpene fractions.³⁴

Africa

The WHO estimates that more than 80% of the African populations rely on traditional medicine for their healthcare needs.³⁵ Traditional medicine has continued to gain acceptability in Africa due to its low cost, availability, and perceived low toxicity.³⁶ There is a lack of adequate data on the use of CAM during the COVID-19 pandemic in Africa. Recently the Madagascar Institute of Applied research linked the use of Artemisia annua (sweet wormwood) in COVID-19.³⁷ Artemisia annua is the source of antimalarial drug artemisinin. Potential widespread use has raised concerns amongst the scientific community in regards to malarial resistance to the drug.³⁸ Leaves of Azadirachta indica, Mangifera indica, Eucalyptus globulus, Carica papaya, Psidium guajava, Citrus reticulate, and Musa paradisiaca steam-inhaled and taken orally were shown in a recent study to be offering symptoms relief and restore physiological and psychological functions.³⁹ Zimbabwean government was reported to have authorised herbalists to treat patients with COVID-19 symptoms raising concerns among national public health experts.⁴⁰

South America

Herbs and spices are very commonly used in Latin American countries. For example, in Brazil, the sales value of herbal drugs reached USD 187 million in 2019, a 3% annual growth compared to the previous year. Mikania glomerata preparations have been known to be used in South America to treat respiratory illnesses such as cough and asthma. Bronchodilator action of the herb has been suggested. These are widely used and prescribed in Brazil, including their use in children. Propolis produced by bees and commonly found in Brazil and exported to Asia including China, has been tipped to potentially interfere with host cell invasion by SARS-CoV-2.

Indigenous communities in South America have also been reported to be using CAM during COVID-19. For example, herbal teas and root teas were reported to have been used by Dâw Indigenous communities in Brazil.⁴⁶ Anecdotal reports of patient experience suggested that they perceived the teas to have helped them cope with the symptoms.⁴⁶ A consortium of Latin-American and Caribbean Center has joined efforts in synthesising the evidence base in regards

to herbal medicines use in COVID-19.47 Other herbs mentioned to have been used by 153 154 Ecuadorian Amazon tribes include umu'co or cat's claw as antipyretic; wild ginger as a cough reliever, and cinchona bark as anti-inflammatory.⁴⁸ 155 156 157 **Europe and the North America** 158 CAM practices amongst communities in Europe and North America are diverse, reflecting the 159 cultural diversities in these countries. In the US alone, it is estimated that over 20,000 different types of herbal products are available.⁴⁹ Herbal products regulations across Europe and North 160 161 America are, however, varied. The US Food and Drug Administration (FDA) classifies herbal preparations as food supplements, and these herbal products do not require pre-marketing 162 163 authorization from the FDA. However, such products should satisfy pre-marketing laws in 164 Europe. 50 This includes adherence to criteria in regards to manufacturing and storage standards in Europe. 165 166 Anecdotal reports have suggested a surge in demand for TCM in the West during the initial 167 phase of the pandemic leading to wholesale suppliers deciding to ration the supply to the 168 169 retailers.⁵¹ In a study conducted in Norway with CAM practitioners, relaxation techniques, 170 prayers, ginger, and fish oils were some of the key practices they recommended to service users. Over 40% of the CAM practitioners in the study admitted that they would not refer COVID-19 171 patients for treatment by a physician.⁵² In the UK, herbs being sold as 'immunity boosters' 172 against coronavirus were reported, which was considered against legal practice given the lack of 173 evidence through clinical trials.⁵³ 174 175 Currently, limited research is being undertaken in the Europe and the North America to identify 176 177 the effectiveness of CAMs including herbal medicines. Models of nano-fibre-based respiratory masks with herbal ingredients to minimise infection rates have been suggested.⁵⁴ Herbal 178 products previously tipped to inactivate the Severe acute respiratory syndrome (SARS) virus and 179 180 dengue fever, such as Andrographis paniculate are known to be amongst those being 181 investigated. 182 **Discussion and conclusions** 183 Currently, the use of CAM in COVID-19 seems to be a common practice, globally. In particular, a 184 185 range of herbal products across different geographical regions and continents are perceived by users to be effective in symptoms relief and/or treatment. Many governments have also formally 186

or informally advocated or authorised the use of CAM in COVID-19, mainly based on their

CAM use in COVID-19 also reflected geographical, cultural, and religious practices.

effectiveness in alleviating other respiratory symptoms or in some occasions on popular beliefs.

187

188

Currently, limited research exists from human clinical trials in regard to the effectiveness of CAM in prevention, treatment, or symptom relief in COVID-19. In addition, gathering patient perspectives and experiences of CAM use in COVID-19 are imperative in informing future practices. Gathering data on common information queries received in community pharmacies, other healthcare settings and those described in internet forms will enable the development of evidence based information sources that can support effective patient counselling and communication practices.

At this time international clinical guidelines do not proactively encourage healthcare professionals to investigate patient use of CAM. It is known that up to $2/3^{rd}$ of CAM users do not declare their CAM use with healthcare professionals.⁶ COVID-19 patients, particularly with comorbidities and using medicines for long-term conditions, can benefit from evidence-based guidelines in regards to drug-herb or herb-disease interactions.

The COVID-19 pandemic has met international health systems with a low level of preparedness and emergency response. Healthcare professionals, including pharmacists, are likely to be sought advice and counselling regarding the use of CAM. Pharmacists have been traditionally offering services for self-care and common ailments including supply of non-prescription medicines. It is imperative that counselling and communications practices by healthcare professionals, including pharmacists, in regards to CAM use are evidence based. Phytochemicals have been integrated into the treatment of long-term health conditions such as cancer and gout. More extensive scientific evidence needs to be sought for their use in COVID-19.

Acknowledgements

215 None

Funding

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19)
- Dashboard with Vaccination Data. WHO. Published 2020. https://covid19.who.int/. Accessed April 22, 2021.
- 224 2. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Non-hospitalized Adults with Early COVID-
- 19: A Randomized Trial. Annals of internal medicine. 2020;173(8):623-631. doi:10.7326/M20-4207.
- 3. Young B, Tan TT, Leo YS. The place for Remdesivir in COVID-19 treatment. The Lancet Infectious Diseases.
- 227 2021;21(1):20-21. doi:10.1016/S1473-3099(20)30911-7.
- 4. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. New England
- 229 Journal of Medicine. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436.
- 5. World Health Organization. Traditional, Complementary and Integrative Medicine. Published 2018.
- 231 https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine#tab=tab_1. Accessed April
- 232 22, 2021.
- 233 6. Alzahrani AS, Price MJ, Greenfield SM, Paudyal V. Global prevalence and types of complementary and
- alternative medicines use amongst adults with diabetes; systematic review and meta-analysis. European Journal
- of Clinical Pharmacology. Published online 2021. doi:10.1007/s00228-021-03097-x.
- 7. Shaikh BT, Hatcher J. Complementary and alternative medicine in Pakistan: Prospects and limitations.
- 237 Evidence-based Complementary and Alternative Medicine. 2005;2(2):139-142. doi:10.1093/ecam/neh088.
- 8. World Health Organization. WHO Global Report on Traditional and Complementary Medicine.; 2019.
- http://apps.who.int/bookorders. Accessed April 22, 2021.
- 9. Paudyal V, Cadogan C, Fialová D, et al. Provision of clinical pharmacy services during the COVID-19
- 241 pandemic: Experiences of pharmacists from 16 European countries. Research in Social and Administrative
- 242 Pharmacy 2021. doi:10.1016/j.sapharm.2020.11.017.
- 10. Dong L, Li YQ, Yang SJ, Liu MN, Liu JL. A Case Study of New Type Coronavirus Pneumonia Based on
- 244 Syndrome Differentiation and Treatment. Pharmacology and Clinics of Chinese Materia Medica. 2020;36(2).
- https://kns.cnki.net/kcms/detail/detail.aspx?doi=10.13412/j.cnki.zyyl.20200312.001. Accessed April 22, 2021.
- 11. National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for
- 247 COVID-19 (Trial Version 7). http://en.nhc.gov.cn/2020-03/29/c_78469.htm. Accessed April 22, 2021.
- 12. Wang C, Sun S, Ding X. The therapeutic effects of traditional Chinese medicine on COVID-19: a narrative
- 249 review. International Journal of Clinical Pharmacy. 2021;43(1):35-45. doi:10.1007/s11096-020-01153-7.
- 250 13. Meng L, Huang J, Qiu F, Sun S. Roles of the Chinese clinical pharmacist during the COVID-19 pandemic.
- Journal of the American College of Clinical Pharmacy. Published online June 4, 2020. doi:10.1002/jac5.1274.
- 14. Nile SH, Kai G. Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the
- 253 COVID-19. Indian Journal of Microbiology. 2020; 30:1-6.
- 15. Hussain S, Saeed A, Ahmed M, Qazi A. Contemporary Role and Future Prospects of Medicinal Plants in the
- 255 Health Care System and Pharmaceutical Industries of Pakistan. Available:
- 256 http://www.telmedpak.com/doctorsarticles. Accessed April 22, 2021.
- 16. Shaikh SH, Malik F, James H, Abdul H. Trends in the use of complementary and alternative medicine in
- Pakistan: A population-based survey. Journal of Alternative and Complementary Medicine. 2009;15(5):545-550.
- 259 doi:10.1089/acm.2008.0232.
- 17. Kadayat TM, Parajuli A, Bist G, Karki R, Shrestha N, Dhami N, omplementary and alternative medicine in
- Nepal: a case study. The Journal of Medicine Use in Developing Countries 2009; 1(4):3-13.
- 18. Charan J, Bhardwaj P, Dutta S, Kaur R, Bist SK, Detha MD, Kanchan T, Yadav D, Mitra P, Sharma P. Use of
- Complementary and Alternative Medicine (CAM) and Home Remedies by COVID-19 Patients: A Telephonic
- 264 Survey. Indian Journal of Clinical Biochemistry. 2021;36(1):108-11. Doi: 10.1007/s12291-020-00931-4.

- 265 19. Ministry of Ayush (India). Guidelines for AYUSH practitioners for COVID-19. Available
- https://www.ayush.gov.in/ayush-guidelines.html. Accessed Apr 23, 2021.
- 267 20. Nugraha RV, Ridwansyah H, Ghozali M, Khairani AF, Atik N. Traditional Herbal Medicine Candidates as
- 268 Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. Evidence-based
- 269 Complementary and Alternative Medicine. 2020;2020. doi:10.1155/2020/2560645.
- 21. Shree P, Mishra P, Selvaraj C, et al. Targeting COVID-19 (SARS-CoV-2) main protease through active
- 271 phytochemicals of ayurvedic medicinal plants–Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy)
- and Ocimum sanctum (Tulsi)—a molecular docking study. Journal of Biomolecular Structure and Dynamics.
- 273 Published online 2020. doi:10.1080/07391102.2020.1810778.
- 27.4 22. World Health Organization. WHO supports scientifically-proven traditional medicine | WHO | Regional Office
- for Africa. https://www.afro.who.int/node/12645. Accessed April 22, 2021.
- 276 23. Hayat M, Hayat MQ, Khan MA, Ashraf M, Jabeen S. Ethnobotany of the Genus Artemisia L. (Asteraceae) in
- Pakistan. Ethnobotany Research and Applications. 2009;7(0):147-162.
- 278 24. Middle East Integrative Health or Complementary and Alternative Medicine Market Report, 2020 2027.
- 279 Grand View Research. Published 2021. https://www.grandviewresearch.com/industry-analysis/middle-east-
- integrative-health-complementary-alternative-medicine-market. Accessed April 22, 2021.
- 25. Alyami HS, Orabi MAA, Aldhabbah FM, et al. Knowledge about COVID-19 and beliefs about and use of
- 282 herbal products during the COVID-19 pandemic: A cross-sectional study in Saudi Arabia. Saudi Pharmaceutical
- 283 Journal. 2020;28(11):1326-1332. doi:10.1016/j.jsps.2020.08.023
- 284 26. Maideen NMP. Prophetic Medicine-Nigella Sativa (Black Cumin Seeds) Potential Herb for COVID-19?
- 285 Journal of Pharmacopuncture. 2020;23(2):62-70. doi:10.3831/KPI.2020.23.010
- 286 27. El Sayed SM, Aboong MS, el Rashedy AG, et al. Promising preventive and therapeutic effects of TaibUVID
- 287 nutritional supplements for COVID-19 pandemic: towards better public prophylaxis and treatment (A retrospective
- study). American Journal of Blood Research. 2020;10(5):266-282.
- 289 28. El Sayed SM, Aboonq MS, Aljehani YT, et al. TaibUVID nutritional supplements help rapid cure of COVID-19
- infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment
- of COVID-19 pandemic. American journal of blood research. 2020;10(6):397-406.
- 29. Alami A el, Fattah A, Abderrahman C, et al. Medicinal Plants used for the Prevention Purposes during the
- 293 Covid-19 Pandemic in Morocco. Journal of Analytical Sciences and Applied Biotechnology. 2020;2(1).
- 30. Yeshurun M. Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection -
- 295 Full Text View ClinicalTrials.gov. U.S Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04731116.
- 296 Accessed April 22, 2021.
- 31. Gomaa A. Complementary Intervention for COVID-19 Full Text View ClinicalTrials.gov. U.S Library of
- 298 Medicine. Published July 27, 2020.
- 299 https://clinicaltrials.gov/ct2/show/NCT04487964?term=Complementary+and+alternative+medicines+use&cond=C
- 300 ovid-19&draw=2&rank=1. Accessed April 22, 2021.
- 30. Bailly C, Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the
- 302 associated respiratory syndrome? Pharmacology and Therapeutics. 2020;214.
- 303 doi:10.1016/j.pharmthera.2020.107618.
- 304 33. Gomaa AA, Abdel-Wadood YA. The potential of glycyrrhizin and licorice extract in combating COVID-19 and
- 305 associated conditions. Phytomedicine Plus. 2021;1(3):100043. doi:10.1016/j.phyplu.2021.100043.
- 306 34. Mostafaie A. Colchicine Plus Phenolic Monoterpenes to Treat COVID-19 Full Text View ClinicalTrials.gov.
- 307 U.S Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04392141. Accessed April 22, 2021.

- 308 35. World Health Organization. WHO Traditional Medicine Strategy 2002 2005.; 2002.
- 309 https://apps.who.int/iris/bitstream/handle/10665/67163/WHO_EDM_TRM_2002.1_eng.pdf?sequence=1&isAllowe
- 310 d=y. Accessed April 22, 2021.
- 31. 36. Mahomoodally MF. Traditional medicines in Africa: an appraisal of ten potent African medicinal plants.
- Evidence-Based Complementary and Alternative Medicine. 2013 Oct;2013. Doi: 10.1155/2013/617459.
- 313 37. Baker A. Unproven Herbal Cure for Coronavirus Is a Hit in Africa https://time.com/5840148/coronavirus-cure-
- 314 covid-organic-madagascar/. Accessed April 22, 2021.
- 315 38. Nordling L. Unproven herbal remedy against COVID-19 could fuel drug-resistant malaria, scientists warn.
- 316 Science. May 6, 2020. doi:10.1126/science.abc6665.
- 39. Orisakwe OE, Orish CN, Nwanaforo EO. Coronavirus disease (COVID-19) and Africa: Acclaimed home
- 318 remedies. Scientific African. 2020;10:e00620. doi:10.1016/j.sciaf.2020.e00620.
- 40. Mavhunga C. Zimbabwe's Government Says Herbal Treatment OK for COVID-19 | Voice of America -
- 320 English. Voice of America. https://www.voanews.com/science-health/coronavirus-outbreak/zimbabwes-
- 321 government-says-herbal-treatment-ok-covid-19. Accessed April 22, 2021.
- 322 41. GlobalData. Herbs, Spices and Seasonings (Seasonings, Dressings and Sauces) Market in Brazil Outlook
- to 2024; Market Size, Growth and Forecast Analytics (updated with COVID-19 Impact). Published February 2021.
- 324 https://www.just-food.com/market-research/herbs-spices-and-seasonings-seasonings-dressings-and-sauces-
- 325 market-in-brazil-outlook-to-2024-market-size-growth-and-forecast-analytics-updated-with-covid-19-
- 326 impact_id320525.aspx. Accessed April 22, 2021.
- 327 42. Agra MDF, Silva KN, Basílio IJLD, de Freitas PF, Barbosa-Filho JM. Survey of medicinal plants used in the
- region Northeast of Brazil. Revista Brasileira de Farmacognosia. 2008;18(3):472-508. doi:10.1590/S0102-
- 329 695X2008000300023.
- 43. Brandão MGL, Cosenza GP, Grael CFF, Netto NL, Monte-Mór RLM. Traditional uses of American plant
- 331 species from the 1st edition of Brazilian Official Pharmacopoeia. Revista Brasileira de Farmacognosia. 2009;19(2
- 332 A):478-487. doi:10.1590/S0102-695X2009000300023.
- 44. Silveira D, Prieto-Garcia JM, Boylan F, et al. COVID-19: Is There Evidence for the Use of Herbal Medicines
- as Adjuvant Symptomatic Therapy? Frontiers in Pharmacology. 2020;11. doi:10.3389/fphar.2020.581840.
- 45. Berretta AA, Silveira MAD, Cóndor Capcha JM, de Jong D. Propolis and its potential against SARS-CoV-2
- infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-
- 337 19. Biomedicine and Pharmacotherapy. 2020;131. doi:10.1016/j.biopha.2020.110622.
- 46. Lila L. With the advance of COVID-19, Indigenous People shelter inside the Forest Greenpeace
- 339 International. GreenPeace. https://www.greenpeace.org/international/story/44836/indigenous-people-refuge-
- amazon-forest-covid19/. Accessed April 22, 2021.
- 47. Portella CFS, Ghelman R, Abdala CVM, Schveitzer MC. Evidence map on the contributions of traditional,
- complementary and integrative medicines for health care in times of COVID-19. Integrative Medicine Research.
- 343 2020;9(3):100473. doi:10.1016/j.imr.2020.100473.
- 48. Riederer R. Fighting COVID-19 in the Amazon, with Herbs and the Internet | The New Yorker. Riederer,
- 345 Rachel. https://www.newyorker.com/news/news-desk/fighting-covid-19-in-the-amazon-with-herbs-and-the-
- internet. Accessed April 22, 2021.
- 347 49. Xiong Y, Gao M, van Duijn B, Choi H, van Horssen F, Wang M. International policies and challenges on the
- 348 legalization of traditional medicine/herbal medicines in the fight against COVID-19. Pharmacological Research.
- 349 2021;166:105472. doi:10.1016/j.phrs.2021.105472.
- 350 50. Alostad AH, Steinke DT, Schafheutle EI. International Comparison of Five Herbal Medicine Registration
- 351 Systems to Inform Regulation Development: United Kingdom, Germany, United States of America, United Arab
- 352 Emirates and Kingdom of Bahrain. Pharmaceutical Medicine. 2018;32(1):39-49. doi:10.1007/s40290-018-0223-0.

- 353 51. Caspani M. U.S. coronavirus threat fuels demand for traditional herbal remedies | Reuters. Reuters.
- Published March 9, 2020. Accessed April 22, 2021. https://www.reuters.com/article/us-health-coronavirus-usa-
- herbs-idUSKBN20W2GR.
- 356 52. Stub T, Jong MC, Kristoffersen AE. The impact of COVID-19 on complementary and alternative medicine
- providers: a cross-sectional survey in Norway. Research Square 2021. DOI: 10.21203/rs.3.rs-61740/v1.
- 358 53. Patel K. Covid-19: Fake "immunity booster" found on sale in London shops BBC News. British Broadcasting
- 359 Corporation. https://www.bbc.com/news/uk-england-london-55318095. Accessed April 22, 2021.
- 360 54. Rahman P. Herbal medicine might help battle against Covid-19 | News | University of Portsmouth. University
- 361 of Portsmouth, UK. https://www.port.ac.uk/news-events-and-blogs/news/herbal-medicine-might-help-battle-
- against-covid-19. Accessed April 22, 2021.
- 363 55. Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacists' adoption into practice of newly reclassified
- 364 medicines from diverse therapeutic areas in Scotland: A quantitative study of factors associated with decision-
- making. Research in Social and Administrative Pharmacy. 2014;10(1):88-105.
- 366 doi:10.1016/j.sapharm.2013.04.007.
- 367 56. Paudyal V, Hansford D, Cunningham S, Stewart D. Pharmacists' perceived integration into practice of over-
- 368 thecounter simvastatin five years post reclassification. International Journal of Clinical Pharmacy.
- 369 2012;34(5):733-738. doi:10.1007/s11096-012-9668-5.
- 370 57. Paudyal V, Cunningham S, Smith KG, MacLure K, Ryan C, Cordina M. Methodological considerations in
- 371 clinical outcomes assessment of pharmacy-based minor ailments management: A systematic review. PLoS ONE.
- 372 2018;13(10). doi:10.1371/journal.pone.0205087.